
| Pair Name | Pterostilbene, Osimertinib | ||
| Phytochemical Name | Pterostilbene (PubChem CID: 5281727 ) | ||
| Anticancer drug Name | Osimertinib (PubChem CID: 71496458 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Pterostilbene, Osimertinib | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Gene Regulation | Down-regulation | Phosphorylation | CDCP1 | hsa64866 |
| Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
| Down-regulation | Phosphorylation | YAP1 | hsa10413 | |
| In Vitro Model | MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 |
| PC-9 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_B260 | |
| NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 | |
| Result | The results of this study indicate that pterostilbene may be used to abrogate the activated resistance pathways of single osimertinib treatment in EGFR-mutation positive NSCLC. Future studies should focus on in vivo translation and confirmation of these results. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). Int J Biol Sci. 2019 Sep 7;15(12):2607-2614. doi: 10.7150/ijbs.32889. | Click |